Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

68.50 -4.31 (-5.93%)
Delayed Quote Updated: 2:25 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Monopar Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Recap: Monopar Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout ↗
The company is working on a treatment for a rare, inherited disease that causes copper to build up in the body. 
Via Investor's Business Daily
News headline image
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
3 Momentum Stocks Soaring Into 2025 and Beyond
Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential. 
Via MarketBeat
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
What's Going On With Monopar Therapeutics Shares Friday? ↗
Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36. 
Via Benzinga
Topics Stocks
News headline image
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder ↗
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today ↗
Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans. 
Via Benzinga
News headline image
MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024 ↗
MNPR stock results show that Monopar Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely ↗
Penny stocks are risky. It’s why we attach a warning to the tail-end of penny stock articles and why the SEC has a warning about them too. 
Via InvestorPlace
Topics Regulatory Compliance
News headline image
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024 ↗
MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023 ↗
MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.